NCT02679196已完成1 期
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma
Karus Therapeutics Limited1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2016年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- The occurrence of dose limiting toxicity (DLT);
研究概览
简要总结
Multiple ascending dose study to evaluate safety/tolerability, pharmacokinetic and pharmacodynamics effects of KA2237 (PI3 Kinase p110β/δ Inhibitor) in patients with B Cell Lymphoma and determine the maximum tolerated dose (MTD) in Part I of the study. In Part II, patients with B cell lymphoma will be treated with KA2237 at the MTD to evaluate safety and efficacy in the patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the screening visit.
- •Has given written consent to participate in the study.
- •Has B-cell lymphoma refractory to or intolerant of established therapy known to provide clinical benefit for their condition and having received rituximab as a single agent or in combination with other therapies.
- •Disease status requirement: Measurable disease defined as the presence of ≥ 1 nodal lesion that measures ≥ 1.5 cm in a single dimension as assessed by X-ray Computed Tomography (CT) (Positron Emission Tomography (PET/CT), or magnetic resonance imaging [MRI]
- •Eastern Co-operative Oncology Group (ECOG) performance status of ≤
- •For men and women of child-bearing potential, willing to use adequate contraception
排除标准
- •Subject is a chronic alcoholic (intake > 35 units of alcohol (>5 bottles of wine weekly)) or drug abuser
- •Subject has any medical or psychiatric condition that, in the opinion of the Investigator, may compromise the subject's ability to participate in this study
- •Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 3 months following the last dose of investigational product
- •Subjects with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal disease (estimated glomerular filtration rate (eGFR) <30ml/min), hepatic (Alanine transaminase (ALT) 2.5 times upper limit of normal (>2.5xULN), bilirubin > 2x ULN), hematological (absolute neutrophil count (ANC) <1.0 x 109/L, platelet count <75x109/L or requires regular platelet transfusions to maintain a platelet count ≥ 75 x 109/L , hemoglobin <9g/dL), endocrine (glycated Haemoglobin (HbA1c)>7% or random glucose >200mg/dL), pulmonary (Forced Expiratory Volume in 1 second (FEV1) <70% of predicted value), cardiac (New York Heart Association (NYHA)) class III/IV, or neurological disease
- •Has had an allogeneic stem cell transplant with current active graft-versus-host-disease.
- •Has known active central nervous system involvement of the malignancy.
- •Has active, serious infection requiring systemic therapy. Patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the treating physician.
- •Has a positive test for human immunodeficiency virus (HIV) antibodies.
- •Has active hepatitis B or C. Patients with serologic evidence of prior exposure are eligible.
- •Disease-related exclusions
- •Had treatment with a short course of corticosteroids (> 10mg daily prednisone equivalents) for symptom relief within 1-week prior to screening.
- •Has poorly controlled diabetes mellitus (HbA1c >7% or random glucose >200mg/dL)
- •Known tuberculosis (TB) disease or latent TB infection
- •Has chronic, active colitis
- •Medication related exclusions
- •Had alemtuzumab therapy within 12-weeks prior to screening.
- •Has taken a medication that is a potent inhibitor or inducer of cytochrome P450 3A4 (CYP3A4) within 1-week prior to screening.
- •The subject has previously participated in this study.
- •The subject has participated or is currently participating in another study of an investigational medicine or medical device (radiotherapy, radio-immunotherapy, biological therapy, chemotherapy), within 4-weeks prior to screening.
研究组 & 干预措施
KA2237
Experimental
Open label treatment with KA2237
干预措施: KA2237 (Drug)
结局指标
主要结局
The occurrence of dose limiting toxicity (DLT);
时间窗: Day 28 of treatment
any event with possible or probable relationship to study drug occurring up to day 28 from the start of treatment as assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03
次要结局
- Concentration (mg/ml) of KA2237 in serum/plasma over time (hours)(24 weeks)
- Concentration (ng/ml) of key cytokine and intracellular signalling markers in immune cell subsets(24 weeks)
- Concentration (mg/ml) of KA2237 in urine over time (hours)(24 weeks)
- Frequency of KA2237 related adverse events and laboratory abnormalities(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis PigmentosaRetinitis PigmentosaRetinitis Pigmentosa SyndromeNCT05392751Endogena Therapeutics, Inc14
已完成
1 期
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid TumoursSolid Tumor, AdultNCT03008018Karus Therapeutics Limited20
已完成
1 期
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)Attention Deficit and Hyperactivity DisorderNCT01174355NeuroDerm Ltd.40
已完成
1 期
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.NeoplasmsNCT00493155Hoffmann-La Roche48
已完成
2 期
PF-06741086 Multiple Dose Study in Severe HemophiliaHemophilia A or BNCT02974855Pfizer27